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Leptin inhibits the contractile response induced by angioten-
sin (Ang) II in vascular smooth muscle cells (VSMCs) of the
aorta. We studied in vitro and ex vivo the role of nitric oxide
(NO) in the effect of leptin on the Ang II-induced vasocon-
striction of the aorta of 10-wk-old Wistar rats. NO and nitric
oxide synthase (NOS) activitywere assessed by theGriess and
3H-arginine/citrulline conversion assays, respectively. Stim-
ulation of inducible NOS (iNOS) as well as Janus kinases/
signal transducers and activators of transcription (JAK/
STAT) and phosphoinositide 3-kinase (PI3K)/Akt signaling
pathways were determined by Western blot. The contractile
responses to Ang II were evaluated in endothelium-denuded
aortic rings using the organ bath system. Changes in intra-
cellular Ca2 were measured in VSMCs using fura-2 fluores-
cence. Leptin significantly (P < 0.01) stimulated NO release
and NOS activity in VSMCs. Leptin’s effect on NO was abol-
ished by the NOS inhibitor, NG-monomethyl L-arginine, or the
iNOS selective inhibitor L-N6-(1-iminoethyl)-lysine. Accord-
ingly, leptin increased iNOS protein expression, with a com-
parable time course with that of NO production and NOS
activity. Leptin also significantly increased STAT3 (P < 0.01)
and Akt (P < 0.001) phosphorylation. Moreover, either the
JAK2 inhibitor, AG490, or the PI3K inhibitor, wortmannin,
significantly (P< 0.05) abrogated the leptin-induced increase
in iNOS protein. Finally, both NG-monomethyl L-arginine and
L-N6-(1-iminoethyl)-lysine inhibitors completely blunted (P <
0.001) the leptin-mediated inhibition of the Ang II-induced
VSMC activation and vasoconstriction. These findings sug-
gest that the endothelium-independent depressor action of
leptin is mediated by an increase of NO bioavailability in
VSMCs. This process requires the up-regulation of iNOS
through mechanisms involving JAK2/STAT3 and PI3K/Akt
pathways. (Endocrinology 148: 324–331, 2007)
OBESITY CONSTITUTES A major risk for the develop-ment of cardiovascular disorders, such as hyperten-
sion and coronary artery disease (1, 2). Several central and
peripheral abnormalities that can explain the development or
maintenance of high blood pressure in obesity have been
identified. Leptin, an adipocyte-derived hormone, is known
to participate in the control of body weight, regulating food
intake and energy expenditure (3). Furthermore, leptin has
been also shown to contribute to blood pressure homeostasis
inducing a pressor response attributable to sympathoactiva-
tion (4) and a depressor response attributable to the vaso-
dilation of conduit and resistance vessels (5, 6). Our group
reported, for the first time, that nitric oxide (NO) represents
the key molecule for the depressor response induced by
leptin (7). Subsequent studies showed that leptin acts on the
endothelium inducing the synthesis of NO through the ac-
tivation of the endothelial NO synthase, hence evoking an
endothelium-dependent vasodilation (8–12). However, be-
cause leptin receptors are also expressed in the underlying
smooth muscle layer, vascular smooth muscle cells (VSMCs)
also represent an important target for the vascular actions of
leptin (13, 14). In previous studies we reported that leptin acts
on VSMCs inhibiting the increase of cytosolic calcium
([Ca2]i) induced by angiotensin II (Ang II) and consequently
blunting the contractile response of the aorta caused by this
potent vasoactive peptide (13, 14). This inhibition of the Ang
II-induced vasoconstriction was shown to be leptin receptor
mediated because no effects of leptin were found in the aorta
and VSMCs obtained from leptin receptor-deficient obese
Zucker rats (13). To date, the postreceptor mechanisms re-
sponsible for this vascular effect of leptin remain unknown.
NO plays an important role in the maintenance of the
vascular tone. In VSMCs, NO is mainly produced by the
inducible NO synthase (iNOS), a Ca2-independent enzyme
that is regulated at transcriptional and posttranscriptional
levels (15). Furthermore, cytokine-induced iNOS up-regula-
tion is mediated, among others, by Janus kinase (JAK)/signal
transducer and activator of transcription (STAT) and phos-
phatidylinositol 3-kinase (PI3K)/Akt signaling pathways
(16–18). On the one hand, the main signaling cascades ac-
tivated by leptin receptors, which belong to the class I cy-
tokine receptor superfamily, include the JAK/STAT and
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PI3K/Akt pathways (18). On the other hand, a functional
relation between leptin and NO has been established in quite
diverse sites and biological actions (19–21). With regard to
the cardiovascular sphere in particular, leptin has been
shown to increase NO synthase (NOS) activity in endothelial
cells (12, 22, 23) and cardiomyocytes (24, 25) through the
activation of PI3K/Akt and JAK2/STAT3 pathways,
respectively.
Given that many of the physiological and pathophysio-
logical effects of Ang II are opposed by NO (26), it seems
plausible that NO operates as the intracellular mediator re-
sponsible for the depressor response of leptin in VSMCs.
Therefore, the aim of the present study was to examine ex vivo
and in vitro the potential role of NO in the inhibition of leptin
on the Ang II-induced contractile response. The effect of
leptin on NO production, NOS activity, and iNOS expression
was measured directly in VSMCs. To gain further insight into
the signaling cascades activated by leptin, the potential in-
volvement of JAK2/STAT3 and PI3K/Akt transduction sig-
nals was analyzed using specific pharmacological inhibitors.
To further corroborate the participation of NO on the vas-
cular actions of leptin, the effect of the NG-monomethyl-l-
arginine (NMMA), a nonselective inhibitor of NOS, and
l-N6-(1-iminoethyl)-lysine (L-NIL), a selective inhibitor of
iNOS, on the inhibitory effect of leptin on the Ang II-induced
VSMC activation and vasoconstriction of the aorta was
analyzed.
Materials and Methods
Animals
Ten-week-old male normotensive Wistar rats (n  30) (breeding
house of the University of Navarra) were used in the present study. Rats
were housed in a temperature-, humidity-, and light-controlled room
with free access to tap water and fed ad libitum with a standard rodent
chow (2014S Teklad global 14% protein rodent maintenance diet; Harlan,
Barcelona, Spain). All experimental procedures conformed with the
European Guidelines for the Care and Use of Laboratory Animals (di-
rective 86/609) and were approved by the Ethical Committee for Animal
Experimentation of the University of Navarra (036/03). Rats were killed
by decapitation. The thoracic aorta was carefully excised, dissected out,
and processed for each study.
Isolation of VSMCs
Primary VSMCs were obtained from the thoracic aorta by the tissue
explants method, as previously described (27). Briefly, the smooth mus-
cle tissue was longitudinally opened and cut in small pieces that were
grown in plastic six-well plates and maintained at 37 C in a humidified
incubator with an atmosphere of 95% air-5% CO2. Tissue explants were
cultured in DMEM containing 20% fetal bovine serum (FBS) (Life Tech-
nologies, Inc., Gaithersburg, MD) and antibiotic-antimycotic products
(10,000 U/ml penicillin G sodium, 10,000 g/ml streptomycin sulfate,
and 25 g/ml amphotericin B as Fungizone in 0.85% saline) (Life Tech-
nologies). The medium was changed initially after 24 h and then every
2–3 d. After about 8–10 d, when cells had formed a confluent monolayer,
they were harvested by addition of 0.05% trypsin, and the culture was
continued up to four to six passages using DMEM containing 10% FBS.
The previous day of each experiment, media of subconfluent cultures
were switched to DMEM containing 0.1% FBS.
Evaluation of NO production and NOS activity
Quiescent VSMCs were stimulated during 30 min with leptin (10
nmol/liter) (PreproTech EC, Inc., Rocky Hill, NJ) in the presence or
absence of NMMA (10 mol/liter) (Sigma, St. Louis, MO) or L-NIL (10
mol/liter) (Sigma). The concentration of leptin as well as that of the
pharmacological NOS inhibitors to carry out the experiments was cho-
sen on the basis of prior experiments performed in our laboratory (13,
14, 28). One sample per assay was used to obtain control responses in
the presence of solvent. Samples of the culture media were collected at
different times (0, 10, 20, and 30 min) for the measurement of nitrates and
nitrites, as an index of NO production, with a commercial kit (Cayman
Chemical, Ann Arbor, MI) based on the Griess reaction following the
manufacturer’s protocol. The inter- and intraassay coefficients of vari-
ation were 6.5 and 3.3%, respectively. Stimulated cells were harvested
and homogenized in a lysis buffer [25 mmol/liter Tris, 1 mmol/liter
EDTA, 1 mmol/liter EGTA (pH 7.40)] supplemented with a protease
inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany)
for the determination of NOS activity. The protein content of the ho-
mogenates was determined by the method of Bradford (29). NOS activity
was measured by the l-[3H]arginine to l-[3H]citrulline conversion assay,
using a commercial kit (Stratagene, La Jolla, CA). The inter- and in-
traassay coefficients of variation were 9.1 and 6.3%, respectively. Briefly,
samples of 20 g protein were incubated at room temperature for 1 h
in the reaction buffer [25 mmol/liter Tris-HCl (pH 7.40), 3 mol/liter
tetrahydrobiopterin, 1 mol/liter flavin adenine dinucleotide reduced,
1mol/liter flavin mononucleotide reduced, 1 mmol/liter nicotinamide
adenine dinucleotide phosphate reduced, 0.6 mmol/liter CaCl2] sup-
plemented with l-[3H]arginine (1 Ci/l) (Amersham Biosciences, Lit-
tle Chalfont, Buckinghamshire, UK). l-[3H]citrulline was quantified by
scintillation. All assays were performed in duplicate.
Western blot studies
Quiescent VSMCs were stimulated for 30 min with leptin (10 nmol/
liter). At different times of the stimulation (0, 2, 5, 10, 20, and 30 min),
cells were harvested, homogenized, and protein content measured as
previously described (13). In some experiments cells were preincubated
for 30 min with the following specific pharmacological inhibitors before
leptin treatment: tyrphostin AG490 (10 mol/liter) (Sigma) for JAK2;
wortmannin (10 mol/liter) (Tocris, Ellisville, MO) for PI3K; actinomy-
cin D (5 g/ml) (Calbiochem, La Jolla, CA) for transcription; and cy-
cloheximide (10 g/ml) (Calbiochem) for protein synthesis. Equal
amounts of protein (30g) were run out in 8% SDS-PAGE, subsequently
transferred to nitrocellulose membranes (Bio-Rad Laboratories, Inc.,
Hercules, CA), and blocked in Tris-buffered saline with Tween 20 con-
taining 5% nonfat dry milk for 1 h at room temperature. Blots were then
incubated overnight at 4 C with Akt, phospho-(Thr308)-Akt (Upstate,
Lake Placid, NY), STAT3, phospho-(Tyr705)-STAT3 (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA), iNOS (BD Transduction Laboratories, San
Jose, CA), or -actin (Sigma) antibodies. The antigen-antibody com-
plexes were visualized using peroxidase-conjugated antimouse or an-
tirabbit IgG antibodies (1:5000) and the enhanced chemiluminescence
detection system (Amersham Biosciences). The intensity of the bands
was determined by densitometric analysis and normalized with -actin
density values.
Measurement of intracellular free Ca2 concentrations
[Ca2]i was measured by fura-2 AM (Molecular Probes, Leiden, The
Netherlands) microfluorometry in combination with digital imaging as
previously reported (27). Basal and Ang II (100 nmol/liter) (Sigma)-
induced changes in the excitation ratio of fura-2 (340/380 nm) were
measured after the preincubation with leptin (0.01, 0.1, 1, and 10 nmol/
liter) during 10 min in VSMCs. The concentration of Ang II to carry out
the experiments was chosen on the basis of previous studies performed
in our laboratory (13, 14, 27). In a subset of experiments, cells were
pretreated for 10 min with NMMA (10 mol/liter) or L-NIL (10 mol/
liter) (Sigma). The [Ca2]i was calculated as described by Grynkiewicz
et al. (30).
Preparation of isolated endothelium-denuded aortic rings
The thoracic aorta was cleaned and placed into Krebs-Henseleit so-
lution as previously reported (13, 14). The endothelium of the aorta was
removed by gently rubbing the intimal surface with the tip of a small
steel stick. The aorta was cut into ring segments (2 to 3 mm in length,
six per rat) that were placed in a vessel containing 20 ml Krebs-Henseleit
solution oxygenated with a 95% O2-5% CO2 mixture and maintained at
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37 C in a thermostated bath (LE 13206 Thermostate; Letica Scientific
Instruments, Barcelona, Spain). Two stainless steel wires were inserted
into the vascular lumen; one was anchored to a stationary support, and
the other was connected to a force-displacement isometric transducer
(Tri 110; Letica Scientific Instruments). Changes in isometric forces were
analyzed and recorded by an Isolated Organs Data Acquisition program
(Proto5; Letica Scientific Instruments). The rings were incubated to
equilibration at a resting tension of 2.5 g for 60 min, with buffer changes
every 15 min during this period. The lack of functional endothelium was
confirmed by the complete absence of relaxation evoked by acetylcho-
line (10 mol/liter) (Sigma) in KCl (80 mmol/liter)-precontracted aortic
rings. The rings were then washed and stretched, if necessary, until a
stable baseline force was obtained. After equilibration, endothelium-
denuded aortic rings were exposed to murine leptin (0.01, 0.1, 1, and 10
nmol/liter) for 30 min, and subsequently the response to Ang II (100
nmol/liter) was evaluated. In a second set of experiments, vessels were
pretreated during 10 min with NMMA (10 mol/liter) or L-NIL (10
mol/liter). One sample per experiment was used to obtain control
responses (100%) in the presence of the solvent. Contractile responses
were evaluated in milligrams of tension and expressed as percentage of
contraction of the KCl (80 mmol/liter)-induced response in each
experiment.
Statistical analysis
Data are presented as mean  sem. The contractile response was
obtained from 10 aortic rings isolated from Wistar rats (n  10). As
otherwise indicated, 10 determinations were performed in isolated
VSMCs obtained from the aorta of Wistar rats (n  5 per experiment).
Statistical differences among mean values were determined using the
two-way or one-way ANOVA, followed by Dunnett’s t test, as appro-
priate. P  0.05 was considered statistically significant. Analyses were
performed by the SPSS/Windows software (version 11.0.1; SPSS Inc.,
Chicago, IL).
Results
Effect of leptin on NO release and NOS activity
The stimulation with leptin induced a statistically signif-
icant increase in both NO production and NOS activity as
compared with basal conditions in VSMCs (Fig. 1). Exposure
to the nonspecific NOS inhibitor, NMMA, and the selective
inhibitor of iNOS, L-NIL, abolished the stimulatory effect of
leptin on NO production and NOS activity.
Effect of leptin on iNOS expression
To establish the potential mechanism of action triggered by
leptin to produce NO, the expression of iNOS protein after
leptin stimulation was studied by Western blotting. Leptin in-
duced a significant increase in iNOS expression in VSMCs, with
a similar time course to that of NO production and NOS activity
(Fig. 2A). To discern whether mRNA and/or protein synthesis
were necessary for the up-regulation of iNOS induced by leptin,
the response of cells after the incubation with the transcription
inhibitor actinomycin D, and the protein synthesis inhibitor,
cycloheximide, was also analyzed. As shown in Fig. 2B, acti-
nomycin D inhibited by approximately 25% the expression of
iNOS induced by leptin. In addition, cycloheximide completely
blunted leptin-induced iNOS expression.
Role of JAK2/STAT3 and PI3K/Akt pathways in leptin-
induced iNOS activation
The ability of leptin to trigger JAK2/STAT3 and PI3K/Akt
was examined by the degree of phosphorylation/activation
of the downstream molecules STAT3 and Akt after leptin
treatment. Leptin activated the phosphorylation of STAT3 in
a time-dependent manner (Fig. 3A), whereas a maximal
phosphorylation of Akt was observed after 10 min of leptin
stimulation with attenuation of the phosphorylation there-
after (Fig. 3B). Because the induction of iNOS can be medi-
ated via JAK2/STAT3 and PI3K/Akt (15–17), we further
investigated the involvement of these transduction signals in
the up-regulation of iNOS induced by leptin. Specific cell-
permeable chemical inhibitors were added to the culture
media before the addition of leptin. The inhibition of the
upstream molecules JAK2 and PI3K with AG490 and wort-
mannin, respectively, significantly reduced leptin-induced
iNOS expression (Fig. 3C). Neither wortmannin nor tyrphos-
tin AG490 modified basal iNOS protein levels (data not
shown).
Effect of leptin on the Ang II-induced increase of [Ca2]i in
VSMCs in the presence of NOS inhibitors
Responses to Ang II (100 nmol/liter) were assessed in
quiescent VSMCs from Wistar rats in the absence or presence
of different concentrations of leptin. Ang II (100 nmol/liter)
induced a maximal increase of [Ca2]i after 2–6 sec of the
stimulation, and baseline or plateau [Ca2]i values were
FIG. 1. Effect of leptin onNOproduction andNOSactivity inVSMCs.
Bar graphs show the differences in the time course of accumulation
of nitrites in the culture media (A) and NOS activity (B) of leptin (10
nmol/liter)-stimulated cells in the presence or absence of the NOS
inhibitor, NMMA (10 mol/liter), and the selective iNOS inhibitor,
L-NIL (10 mol/liter). Data are expressed as mean SEM of 10 assays
performed in isolated VSMCs from the aorta of Wistar rats (n  5).
Each assay was performed in duplicate. *, P  0.05, **, P  0.01 vs.
unstimulated cells.
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achieved within the following 30–40 sec (Fig. 4). Leptin
reduced in a concentration-dependent manner the peak of
[Ca2]i after Ang II (100 nmol/liter) stimulation (Fig. 4A).
The adipokine also accelerated the recovery rate to basal
[Ca2]i values (Fig. 4, B and C). Pretreatment with either the
NOS inhibitor, NMMA (Fig. 4B), or the selective iNOS
inhibitor, L-NIL (Fig. 4C), blunted the depressor action of
leptin (10 nmol/liter) on Ang II (100 nmol/liter)-induced
VSMC activation. NOS inhibitors did not modify the Ang
II-induced peak of [Ca2]i or the return to basal calcium
levels.
Effect of leptin on Ang II-induced contractile response in the
presence of NOS inhibitors
The vascular response to Ang II (100 nmol/liter) was also
evaluated in endothelium-denuded aortic rings after the pre-
incubation with different concentrations of leptin for 30 min.
FIG. 2. Effect of leptin on iNOS expression in VSMCs. A, Histograms
illustrate the differences in the time course of iNOS expression in
VSMCs stimulated with leptin (10 nmol/liter). B, Effect of the mRNA
synthesis inhibitor, actinomycin D (5 g/ml), and the protein syn-
thesis inhibitor cycloheximide (10 g/ml) on the up-regulation of
iNOS evoked by leptin. Representative blots of 10 replicates are
shown on the top of the histograms. Each bar represents mean SEM
for 10 determinations performed in isolated VSMCs from the aorta of
Wistar rats (n  5). *, P  0.05, **, P  0.01, ***, P  0.001 vs.
unstimulated cells; †, P 0.05, ††, P 0.01 vs. leptin-stimulated cells
in the absence of inhibitors.
FIG. 3. Western blot analysis showing the effect of leptin (10 nmol/
liter) on STAT3 (A) and Akt (B) phosphorylation in VSMCs. C, Effect
of the JAK2 inhibitor AG490 (10 mol/liter) and the PI3K inhibitor
wortmannin (10 mol/liter) on the iNOS expression induced by leptin
in VSMCs. Representative blots of 10 replicates are shown on the top
of the histograms. Each bar represents mean  SEM for 10 determi-
nations performed in isolated VSMCs from the aorta of Wistar rats
(n 5). *, P 0.05, **, P 0.01, ***, P 0.001 vs. unstimulated cells;
†, P  0.05, ††, P  0.01 vs. leptin-stimulated cells in the absence of
inhibitors.
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Leptin inhibited in a concentration-dependent manner the
Ang II (100 nmol/liter)-induced vasoconstriction in Wistar
rats (Fig. 5A). In addition, preincubation of endothelium-
denuded aortic rings with leptin (10 nmol/liter) for 30 min
induced a significant (P  0.030) decrease in the basal wall
tension (17  2 vs. 21  4 mg).
The effect of leptin (10 nmol/liter) on the Ang II-induced
vascular response was reexamined in the presence of the
NOS inhibitors NMMA and L-NIL (Fig. 5, B and C). Both
NOS inhibitors completely abolished the inhibitory effect of
leptin on the Ang II-mediated vasoconstriction. Moreover,
the presence of NMMA or L-NIL blunted the decrease of the
passive vasomotor tone induced by leptin (16  3 and 16 
5 vs. 21  4 mg, respectively). The passive wall tension of
endothelium-denuded aortic rings was not affected by the
presence of NOS inhibitors.
FIG. 4. Impact of NOS inhibitors on the depressor action of leptin on Ang II-induced increase in [Ca2]i of VSMCs. A, Line graphs show the
Ang II (100 nmol/liter)-induced changes in [Ca2]i in VSMCs fromWistar rats in the absence or after preincubationwith different concentrations
of leptin. Line graphs show the differences in the time course of Ang II-induced calcium mobilization in the absence or presence of leptin (10
nmol/liter), the NOS inhibitor NMMA (10 mol/liter) (B), or the selective iNOS inhibitor L-NIL (10 mol/liter) (C). Maximal stimulated [Ca2]i
occurred at 2–6 sec, and the recovery to basal concentrations was measured thereafter. Values are expressed as mean  SEM of independent
experiments performed in 10–15 cells/group isolated from the aorta of Wistar rats (n  4). *, P  0.05, **, P  0.01, ***, P  0.001 vs. Ang
II control response in the absence of inhibitors.
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Discussion
Several ex vivo studies have reported that leptin exerts a
direct vasodilation through different endothelial mecha-
nisms, depending on the specific vascular bed at which it
acts. In the aorta and coronary arteries, leptin reportedly
induces vasodilation via NO (8, 9, 31), whereas the relaxation
induced by the hormone in mesenteric arteries is mediated
by the endothelium-derived hyperpolarizing factor (8, 32).
Moreover, leptin treatment in vivo has been shown to reverse
the endothelial dysfunction of leptin-deficient obese (ob/ob)
mice by increasing NO bioavailability in vessels (10). How-
ever, previous data suggest that the smooth muscle layer also
constitutes an important target for the vasorelaxant actions
of leptin (13). The present study has further explored the
complex mechanisms by which leptin exerts its depressor
action operating directly on VSMCs.
Our data show, for the first time, that leptin induces the
synthesis of NO in VSMCs through the activation of iNOS
with leptin-induced NO production and NOS activity in
VSMCs being completely prevented by an iNOS inhibitor.
Furthermore, leptin increased the synthesis of iNOS protein
mainly at a posttranscriptional level because the inhibition of
RNA transcription reduced only 25% of the leptin-induced
iNOS expression, whereas the inhibition of the translation
totally blunted the leptin-induced iNOS up-regulation. The
ability of leptin to up-regulate the iNOS isoform has been
shown in other cell types such as chondrocytes, glioma cells,
macrophages, or cells from the gastric mucosa (33–36).
To gain further insight into the mechanisms by which
leptin promotes iNOS up-regulation, we evaluated the sig-
naling cascades potentially involved. In VSMCs, JAK2 ki-
nases induce the tyrosine phosphorylation and nuclear trans-
location of the STAT3 transcription factor, which binds to its
response element in the iNOS gene promoter, inducing iNOS
transcription (15, 17). On the other hand, the phosphoryla-
tion of Akt has been shown to induce a concomitant activa-
tion of the transcription factor nuclear factor-B, a pivotal
regulator of iNOS expression (37). Recent studies reported
that the activation of JAK2/STAT3 and PI3K/Akt transduc-
tion signals is related to the induction of iNOS by leptin in
rat cardiomyocytes and human chondrocytes (25, 33). Our
findings show that leptin treatment induced the phosphor-
ylation/activation of the STAT3 and Akt downstream mol-
ecules. A similar pattern of phosphorylation after acute stim-
ulation with leptin has been found for STAT3 in rat VSMCs
(25, 38) and Akt in isolated aortic rings (12). Furthermore, the
inhibition of the JAK2 and PI3K upstream molecules de-
creased the expression of iNOS evoked by leptin in VSMCs.
Taken together, we conclude that activation of the JAK2/
STAT3 and PI3K/Akt pathways induced by leptin consti-
tutes an early step for the up-regulation of iNOS, which is in
accordance with studies performed by other authors (25, 33).
The vasoconstrictive action of Ang II is based on its ability
to elevate the [Ca2]i in the smooth muscle layer (39). The
intracellular mechanisms triggered by Ang II to increase the
[Ca2]i in VSMCs after binding the Ang II receptor type 1
include the rapid release of calcium sequestered in the sar-
coplasmic reticulum and the additional increase of the cal-
cium influx from the extracellular compartment. Our group
previously tested the effect of leptin on the contractile re-
sponse of Ang II and other vasoconstrictors, such as nor-
adrenaline and endothelin-1 (13, 14, 40). The Ang II-induced
vasoconstriction was inhibited by leptin in the aorta, whereas
no effects of leptin were found on the noradrenaline- and
endothelin-1-induced contraction (13, 40). Leptin attenuates
the Ang II-induced contraction by blocking the release of
Ca2 sequestered in the intracellular stores, the major mech-
anism used by Ang II to increase the [Ca2]i (39). Therefore,
the lack of effect of leptin on the contraction of noradrenaline
FIG. 5. Impact of NOS inhibitors on the depressor action of leptin on
Ang II-induced contractile response. A, Line graphs show the inhi-
bition exerted by leptin on the Ang II (100 nmol/liter)-induced vaso-
constriction of endothelium-denuded aortic rings. Both NMMA (10
mol/liter) (B) and L-NIL (10 mol/liter) (C) blunted the depressor
action of leptin (10 nmol/liter) on the Ang II (100 nmol/liter)-induced
response in endothelium-denuded vessels. Data are expressed as
mean  SEM of the contractile response of 10 aortic preparations
obtained from Wistar rats (n  10). *, P  0.05, **, P  0.01 vs. Ang
II control response in the absence of inhibitors.
Rodrı´guez et al. • Leptin Inhibits Angiotensin II Effects Endocrinology, January 2007, 148(1):324–331 329
and endothelin-1 may be ascribed to the fact that these va-
soconstrictors exert their contractile properties mainly via a
Ca2 influx from the extracellular compartment.
The intracellular signaling cascade underlying the depres-
sor action of leptin on Ang II-induced vasoconstriction has
not been completely disentangled. The potential role of NO,
a key modulator of the vascular tone, on this effect of leptin
has been addressed by several groups. On the one hand, NO
has been shown to induce a direct vasodilation through
mechanisms that include the activation of the guanylyl cy-
clase that converts GTP into cGMP in VSMCs (41). On the
other hand, NO has been observed to reduce the vasocon-
striction induced by Ang II by activating calcium clearing
mechanisms in VSMCs, such as the sarcoplasmic Ca2-AT-
Pase and Na/Ca2 exchanger, and reducing intracellular
calcium transients, decreasing phospholipase C and inositol
1,4,5-trisphosphate receptor activity (26). Interestingly, our
data indicate that leptin induced a decrease of the passive
wall tension of the endothelium-denuded aorta that was
inhibited in the presence of NOS inhibitors. Moreover, under
NOS activity blockade, the inhibition of leptin on the Ang
II-induced increase of [Ca2]i in VSMCs and the vasocon-
striction of endothelium-denuded aortic rings was com-
pletely blunted. Thus, our data provide evidence that the
depressor action of leptin in the smooth muscle layer of the
aorta produces a direct vasorelaxant effect as well as a re-
duction of the vasoconstrictor potential of Ang II through
NO-dependent mechanisms. Similar findings of hypotensive
effects of leptin via NO have been reported in rat myocar-
dium (24), kidneys (42), and endothelium of conduit vessels
(aorta) (8, 9) and resistance vessels (mesenteric and coronary
arteries) (8, 9, 43). Taken together, these data support the
notion that NO represents a key mediator of the cardiovas-
cular effects of leptin (5).
The effect of the inhibition of the upstream molecules JAK2
and PI3K was not directly tested in the vascular preparations.
Nonetheless, our data show that iNOS activation is necessary
for the depressor action of leptin on the Ang II-induced
vasoconstriction in isolated aortic rings. Interestingly, we
found that leptin-stimulated up-regulation of iNOS was ef-
fectively blocked by pharmacological inhibitors of JAK2
(AG490) and PI3K (wortmannin), which is in accordance
with previously published studies performed in isolated
myocytes (25, 33). Thus, our findings suggest that the JAK2/
STAT3 and PI3K/Akt pathways are required for this vas-
cular effect of leptin, although the participation of other
transduction signals involved in the up-regulation of iNOS
may not be ruled out.
It has been recently reported that oxidative stress further
participates in the Ang II-induced vasoconstriction (44). Ang
II induces the generation of reactive oxygen species, which
scavenge NO to reduce NO bioavailability and generate the
potent oxidative peroxynitrite radical, known to play rele-
vant roles in vascular pathophysiology (44). Our findings
support that leptin counteracts the Ang II-induced vasocon-
striction by increasing NO biodisponsibility in the vascular
wall of normotensive rats. However, in spontaneously hy-
pertensive rats, leptin resistance has been observed at the
VSMC level in relation to a loss of antagonism of the Ang
II-induced contractile response (14). Taken together, under
physiological conditions, NO produced by leptin may ac-
count for the decrease of Ang II-induced vasoconstriction to
maintain the vascular tone (Fig. 6). However, obesity-asso-
ciated hypertension is characterized by hyperleptinemia,
leptin resistance, and stimulation of the renin-angiotensin
system (45–47). Thus, in the context of obesity-associated
hypertension, hyperleptinemia may constitute a compensa-
tory mechanism for vascular leptin resistance due to an ex-
acerbated response to Ang II that decreases NO bioavail-
ability and hence attenuates the vascular effects of leptin.
In conclusion, our results provide evidence that the de-
pressor action of leptin on the Ang II-induced contractile
response is mediated by NO-dependent mechanisms. Thus,
leptin exerts a vasodilator effect on vascular beds by increas-
ing NO release not only at the endothelial level but also in
the smooth muscle layer. This statement is supported by the
findings reported herein: 1) leptin stimulates the JAK2/
STAT3 and PI3K/Akt pathways, enhancing iNOS expression
and activity; 2) this effect takes place mainly at a posttran-
scriptional level; and 3) the subsequent NO production
blunts the Ang II-induced VSMCs activation and
vasoconstriction.
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